Prophylactic antibiotics
PreclinicalSmall molecule
Prophylactic antibiotics is one of 12 small molecule programs targeting Acute Liver Failure. It is currently in Preclinical.
1
Indications
4
Total Trials
1
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
16 competitors in Acute Liver Failure
#DrugCompanyPhaseTrials
1Cysteine Hydrochloride
NovartisApproved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
L-Ornithine L-Aspartate
IInstitute of Liver and Biliary Sciences, India
Phase 2
Ornithine Phenylacetate
OOcera Therapeutics
Phase 2
Plasma Exchange
SanofiPreclinical
Granulocyte Colony-Stimulating Factor
SanofiPreclinical
Exosome
PParacrine Therapeutics Dermatology Pte. Ltd.
Phase 1
Stemchymal
SSteminent Biotherapeutics Inc.
Phase 1
N-Acetyl-L-Cysteine
PPeking University People's Hospital
Preclinical
N-Acetylcysteine (NAC) Treatment
TThe First Affiliated Hospital of Soochow University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Acute Liver Failure1 trial
Antibiotics1 trial
Prophylactic Antibiotics in Endoscopic Secondary Prevention of Gastroesophageal Variceal Bleeding
Active, not recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·N/A·NCT06437964·226 enrolled
Bone1 trial
Platform Switched Implant and Bone Level Alteration
Unknown status·—·N/A·NCT02867982·36 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Prophylactic antibiotics. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details